Announced
Completed
Financials
Sources
Tags
Completed
Private Equity
gene therapy
United States
Friendly
Private
Minority
Acquisition
Venture Capital
Biotechnology
Domestic
Synopsis
EcoR1 Capital, a venture capital firm, led a $115m Series B financing round in Neurogene, a genetic medicines provider. Existing investors Redmile Group, Samsara BioCapital, Cormorant Asset Management and an undisclosed healthcare investment fund also participated. New investors include funds and accounts managed by BlackRock, funds managed by Janus Henderson Investors, Casdin Capital, Avidity Partners, Ascendant BioCapital, Arrowmark Partners, and Alexandria Venture Investments. “Gene therapy has generated tremendous hope for the many families and patients with severe genetic disorders. We believe our focus on improved product design, innovative technology, cutting-edge vector manufacturing and premier analytics will help fulfill the potential of genetic treatments. Proceeds from this round of financing will help us execute on our mission to develop safe and effective genetic therapies for patients and families living with neurological diseases,” Rachel McMinn, Ph.D., Neurogene Founder and Chief Executive Officer.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.